|
|
Zymeworks Provides Corporate Update And Reports First Quarter 2024 Financial Results
|
Vancouver, BC, May 10, 2024--Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, reported financial results for the three months ended March 31, 2024 and provided a summary of recent business highlights.
|
|
|
|
|
|
|
|
|
Zymeworks Added To Nasdaq Biotechnology Index
|
Vancouver, BC, December 29, 2023--Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced it has been added to the Nasdaq Biotechnology Index.
|
|
|
|
|
|
|
Zymeworks Joins the Russell 3000, Russell 2000, And Russell Microcap Indexes
|
Vancouver, BC, July 14, 2023--Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced that it has recently joined both the Russell 3000, Russell 2000®, and the Russell Microcap® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective June 26, 2023.
|
|
|
|
|